The rise of GLP-1 drugs like Ozempic and Wegovy has revolutionized weight loss treatment, but a recent study reveals a potential pitfall: users may be neglecting exercise. Researchers from HSHS Saint John’s Hospital in Illinois and other institutions analyzed Fitbit data from individuals with obesity prescribed GLP-1 medications. Their findings indicate a concerning trend: physical activity significantly decreases after starting these drugs.
The study, which will be presented at ENDO 2026, the Endocrine Society's annual meeting, highlights a paradox. While exercise isn't the primary driver of weight loss, it has long been recommended alongside diet for its role in preserving muscle mass and physical strength. However, the addition of GLP-1 therapy has proven more effective on average, leading researchers to investigate how this might affect exercise habits.
Analyzing data from 753 volunteers in the All of Us research program, the team found a decline in physical activity among GLP-1 users. Daily steps dropped from 5,047 to 4,487, and moderate-to-vigorous activity decreased from 28 minutes to 22 minutes. This trend was more pronounced among men and individuals with musculoskeletal pain.
The implications are significant. Exercise is a cornerstone of health, regardless of weight or medication status. Yet, the study suggests that many GLP-1 users are discontinuing their exercise routines, which could lead to muscle loss and other health issues. The researchers emphasize the need for targeted interventions that encourage physical activity alongside pharmacological therapy.
One of the study's key takeaways is that weight loss alone may not be sufficient to promote increased physical activity. This raises a deeper question: how can we best support individuals on GLP-1 therapy to maintain their exercise habits? The answer lies in a holistic approach that combines medication with lifestyle modifications, ensuring that the benefits of GLP-1 therapy are maximized while minimizing potential drawbacks.
In conclusion, while GLP-1 drugs offer a promising solution for weight loss, it is crucial to address the potential decline in physical activity. By integrating exercise into the treatment plan and providing targeted interventions, we can ensure that patients not only achieve their weight loss goals but also maintain their overall health and well-being.
